Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation

Br J Haematol. 2012 May;157(3):407-10. doi: 10.1111/j.1365-2141.2011.09016.x. Epub 2012 Jan 9.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Benzamides
  • Drug Resistance
  • Female
  • Harringtonines / administration & dosage
  • Homoharringtonine
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Mutation
  • Neoplasm, Residual
  • Piperazines / therapeutic use
  • Pyrimidines / administration & dosage
  • Pyrimidines / therapeutic use

Substances

  • Benzamides
  • Harringtonines
  • Piperazines
  • Pyrimidines
  • Homoharringtonine
  • Imatinib Mesylate
  • nilotinib